Nano-carriers for the Treatment of Tuberculosis.

Q3 Medicine
Sadaf J Gilani, Ameeduzzafar, Mohammed Jafar, Kashif Shakil, Syed S Imam
{"title":"Nano-carriers for the Treatment of Tuberculosis.","authors":"Sadaf J Gilani,&nbsp;Ameeduzzafar,&nbsp;Mohammed Jafar,&nbsp;Kashif Shakil,&nbsp;Syed S Imam","doi":"10.2174/1574891X12666170427120230","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Nano size based drug delivery systems are an emerging technique with the potential to develop new strategies involving handling of drugs at the nanometer scale. There are many nano-based drug delivery systems that have been extensively reported as drug carriers for the treatment of tuberculosis.</p><p><strong>Methods: </strong>There are numerous nano sized drug delivery systems like lipid nanoparticles, polymeric micelle, carbon nanotubes and polymeric nanoparticles that have been reported for a long time to treat diseases. There are a number of drawbacks in conventional TB dosage forms such as the development of multiple drug resistance, resulting in intolerable toxicity and high drug dose required. So, to overcome the drawbacks of conventional therapy, there is a need for a new drug delivery system with an aim to reduce the side effects of drug treatment. Nano-sized based drug delivery systems have considerable potential for the treatment of tuberculosis. These delivery systems have several advantages like high stability, high loading capacity, the feasibility of incorporation of both hydrophilic and hydrophobic drugs, and feasibility of variable routes of administration, and prolonged drug release from the matrix. These advantages enable enhanced drug solubility, bioavailability, reduced dosing frequency, high targeting, and may resolve the problem of non adherence to prescribed therapy, which is one of the major obstacles in the control of tuberculosis epidemics.</p><p><strong>Conclusion: </strong>This article gives an exhaustive review of patents and research papers published over the years on the challenges, the current treatment therapy of the disease faces, and potential advantages of nano sized formulations to offer more effective treatment and prevention for tuberculosis.</p>","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent patents on anti-infective drug discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1574891X12666170427120230","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Nano size based drug delivery systems are an emerging technique with the potential to develop new strategies involving handling of drugs at the nanometer scale. There are many nano-based drug delivery systems that have been extensively reported as drug carriers for the treatment of tuberculosis.

Methods: There are numerous nano sized drug delivery systems like lipid nanoparticles, polymeric micelle, carbon nanotubes and polymeric nanoparticles that have been reported for a long time to treat diseases. There are a number of drawbacks in conventional TB dosage forms such as the development of multiple drug resistance, resulting in intolerable toxicity and high drug dose required. So, to overcome the drawbacks of conventional therapy, there is a need for a new drug delivery system with an aim to reduce the side effects of drug treatment. Nano-sized based drug delivery systems have considerable potential for the treatment of tuberculosis. These delivery systems have several advantages like high stability, high loading capacity, the feasibility of incorporation of both hydrophilic and hydrophobic drugs, and feasibility of variable routes of administration, and prolonged drug release from the matrix. These advantages enable enhanced drug solubility, bioavailability, reduced dosing frequency, high targeting, and may resolve the problem of non adherence to prescribed therapy, which is one of the major obstacles in the control of tuberculosis epidemics.

Conclusion: This article gives an exhaustive review of patents and research papers published over the years on the challenges, the current treatment therapy of the disease faces, and potential advantages of nano sized formulations to offer more effective treatment and prevention for tuberculosis.

治疗肺结核的纳米载体。
背景:基于纳米尺寸的药物输送系统是一种新兴技术,具有开发涉及纳米尺度药物处理的新策略的潜力。有许多基于纳米的药物递送系统已经被广泛报道为治疗结核病的药物载体。方法:有许多纳米级的药物传递系统,如脂质纳米颗粒、聚合物胶束、碳纳米管和聚合物纳米颗粒,已经报道了很长时间用于治疗疾病。传统的结核病剂型存在许多缺点,例如产生多重耐药性,导致无法忍受的毒性和所需的高药物剂量。因此,为了克服传统治疗的缺点,需要一种新的药物输送系统,以减少药物治疗的副作用。纳米尺度的药物输送系统在治疗结核病方面具有相当大的潜力。这些给药系统具有高稳定性、高负载能力、亲水和疏水药物结合的可行性、可变给药途径的可行性以及药物从基质中释放的延长性等优点。这些优点可以增强药物溶解度、生物利用度、减少给药频率、高靶向性,并可能解决不遵守处方治疗的问题,这是控制结核病流行的主要障碍之一。结论:本文对多年来发表的专利和研究论文进行了详尽的综述,介绍了纳米制剂在结核病治疗和预防方面面临的挑战、目前的治疗方法以及纳米制剂的潜在优势。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Recent patents on anti-infective drug discovery
Recent patents on anti-infective drug discovery Medicine-Pharmacology (medical)
CiteScore
2.40
自引率
0.00%
发文量
1
期刊介绍: Recent Patents on Anti-Infective Drug Discovery publishes review articles on recent patents in the field of anti-infective drug discovery e.g. novel bioactive compounds, analogs & targets. A selection of important and recent patents on anti-infective drug discovery is also included in the journal. The journal is essential reading for all researchers involved in anti-infective drug design and discovery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信